Literature DB >> 10950780

Intranasal immunization with gonococcal outer membrane preparations reduces the duration of vaginal colonization of mice by Neisseria gonorrhoeae.

M Plante1, A Jerse, J Hamel, F Couture, C R Rioux, B R Brodeur, D Martin.   

Abstract

Nasal immunization was studied to determine if it could elicit an immune response capable of preventing vaginal colonization by Neisseria gonorrhoeae or of reducing its duration in the estradiol-treated mouse model. Nasal administration of gonococcal outer membrane (OM) preparations induced the development of systemic and vaginal immune responses that were directed mainly against a limited number of gonococcal OM proteins. The impact of nasal immunization on vaginal colonization by N. gonorrhoeae was evaluated by use of an experimental model, in which mice were treated with estradiol to prolong the infection. Bacterial clearance was significantly faster for mice immunized intranasally with N. gonorrhoeae OM preparations (4.0+/-2.5 days) than for control mice (8.5+/-4.3 days). The estradiol-treated mouse model may serve as a useful tool for the evaluation of potential gonococcal vaccine candidates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10950780     DOI: 10.1086/315801

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  26 in total

1.  Immunogenicity of gonococcal transferrin binding proteins during natural infections.

Authors:  Gregory A Price; Marcia M Hobbs; Cynthia Nau Cornelissen
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

Review 2.  Identification and characterization of gonococcal iron transport systems as potential vaccine antigens.

Authors:  C N Cornelissen
Journal:  Future Microbiol       Date:  2008-06       Impact factor: 3.165

3.  Protective immunity against Chlamydia trachomatis can engage both CD4+ and CD8+ T cells and bridge the respiratory and genital mucosae.

Authors:  Catarina V Nogueira; Xuqing Zhang; Nicholas Giovannone; Erica L Sennott; Michael N Starnbach
Journal:  J Immunol       Date:  2015-01-30       Impact factor: 5.422

4.  Vaccines against gonorrhea: current status and future challenges.

Authors:  Ann E Jerse; Margaret C Bash; Michael W Russell
Journal:  Vaccine       Date:  2013-09-06       Impact factor: 3.641

5.  Neisseria gonorrhoeae NspA induces specific bactericidal and opsonic antibodies in mice.

Authors:  Guocai Li; Hongmei Jiao; Guihua Jiang; Jing Wang; Litian Zhu; Rushan Xie; Hua Yan; Hongju Chen; Mingchun Ji
Journal:  Clin Vaccine Immunol       Date:  2011-09-14

6.  Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice.

Authors:  Gregory A Price; Michael W Russell; Cynthia Nau Cornelissen
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

7.  Regulatory T cells are locally induced during intravaginal infection of mice with Neisseria gonorrhoeae.

Authors:  Mónica Imarai; Enzo Candia; Carolina Rodriguez-Tirado; Javier Tognarelli; Mirka Pardo; Tomas Pérez; Daniel Valdés; Sebastián Reyes-Cerpa; Pablo Nelson; Claudio Acuna-Castillo; Kevin Maisey
Journal:  Infect Immun       Date:  2008-09-29       Impact factor: 3.441

8.  Local and humoral immune responses against primary and repeat Neisseria gonorrhoeae genital tract infections of 17beta-estradiol-treated mice.

Authors:  Wenxia Song; Sara Condron; Brian T Mocca; Sandra J Veit; Dawn Hill; Asima Abbas; Ann E Jerse
Journal:  Vaccine       Date:  2008-08-30       Impact factor: 3.641

Review 9.  Summary and Recommendations from the National Institute of Allergy and Infectious Diseases (NIAID) Workshop "Gonorrhea Vaccines: the Way Forward".

Authors:  Lee M Wetzler; Ian M Feavers; Scott D Gray-Owen; Ann E Jerse; Peter A Rice; Carolyn D Deal
Journal:  Clin Vaccine Immunol       Date:  2016-08-05

10.  Extragenital manifestations of Neisseria gonorrhoeae.

Authors:  Steven E Spencer; Margaret C Bash
Journal:  Curr Infect Dis Rep       Date:  2006-03       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.